Tozorakimab clinical trials for COPD

Clinical trial analyses for tozorakimab, an investigational anti-interleukin-33 monoclonal antibody, have demonstrated efficacy in treating chronic obstructive pulmonary disease (COPD).

Initial integrated analysis of the phase 3 OBERON and TITANIA trials indicated that the drug significantly reduces segmental mucus plugging in patients by inhibiting both reduced and oxidized forms of interleukin-33. This finding aligns with results showing a reduction in moderate or severe COPD exacerbations by approximately 30% compared to a placebo.

Subsequent integrated analysis of the OBERON, TITANIA, and PROSPERO trials presented at the CHEST 2026 Annual Meeting showed that tozorakimab sustained reductions in exacerbations for up to 104 weeks. In the overall population of current and former smokers, the annualized exacerbation rate was 0.26 for those receiving tozorakimab versus 0.36 for the placebo group. However, the drug narrowly missed its primary endpoint for severe exacerbations specifically in former smokers, with a rate of 0.26 for tozorakimab compared to 0.33 for the placebo.